ovarian reserve reduced oocyte availability
Conditions
Interventions
None listed
Sponsors
Medisch Universitair Ziekenhuis Maastricht
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: - IVF/PGD treatment for a BRCA1/2 mutation, both female and male mutation carriers - IVF/PGD treatment because of an autosomal dominant genetic disorder transmitted by the male - IVF treatment, including ICSI, for male subfertility
Exclusion criteria
Exclusion criteria: - Previous diagnosis of female subfertility in controls - Known hereditary disease other than due to BRCA1/2-mutations in the female - Known history of a malignancy in the female - History of cancer treatment in the female - Non-Dutch couples, not able to understand the patient information to give informed consent properly
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| a) determine the presence of apoptosis, DNA damage, impaired spindle formation or other cell division defects present in the studied biological samples compared to controls. b) exploration and identification of the molecular pathways associated with reduced ovarian reserve and oocyte/embryo competence in BRCA1/2-mutation carriers. | — |
Countries
Netherlands
Outcome results
None listed